NZ552510A - N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer - Google Patents

N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer

Info

Publication number
NZ552510A
NZ552510A NZ552510A NZ55251005A NZ552510A NZ 552510 A NZ552510 A NZ 552510A NZ 552510 A NZ552510 A NZ 552510A NZ 55251005 A NZ55251005 A NZ 55251005A NZ 552510 A NZ552510 A NZ 552510A
Authority
NZ
New Zealand
Prior art keywords
imidazol
benzyl
phenyl
dimethylpropyl
amino
Prior art date
Application number
NZ552510A
Other languages
English (en)
Inventor
Weibo Wang
Paul A Barsanti
Yi Xi
Rustum S Boyce
Sabina Pecchi
Nathan Brammeier
Megan Phillips
Kris Mendenhall
Kelly Wayman
Liana Marie Lagniton
Ryan Constantine
Hong Yang
Elizabeth Mieuli
Savithri Ramurthy
Elisa Jazan
Anu Sharma
Jain Rama
Sharadha Sabramanian
Paul Renhowe
Kenneth Walter Bair
David Duhl
Annette Walter
Tinya Abrams
Kay Huh
Eric Martin
Mark Knapp
Vincent Le
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34980173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ552510(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of NZ552510A publication Critical patent/NZ552510A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ552510A 2004-06-18 2005-06-20 N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer NZ552510A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58092704P 2004-06-18 2004-06-18
PCT/US2005/022062 WO2006002236A1 (en) 2004-06-18 2005-06-20 N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ552510A true NZ552510A (en) 2010-12-24

Family

ID=34980173

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ552510A NZ552510A (en) 2004-06-18 2005-06-20 N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer

Country Status (21)

Country Link
US (3) US7576221B2 (cg-RX-API-DMAC7.html)
EP (1) EP1765789B1 (cg-RX-API-DMAC7.html)
JP (2) JP4836280B2 (cg-RX-API-DMAC7.html)
KR (1) KR101170925B1 (cg-RX-API-DMAC7.html)
CN (1) CN1993331A (cg-RX-API-DMAC7.html)
AU (1) AU2005258135B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510929A (cg-RX-API-DMAC7.html)
CA (1) CA2571002A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP077183A (cg-RX-API-DMAC7.html)
ES (1) ES2409345T3 (cg-RX-API-DMAC7.html)
IL (1) IL180147A0 (cg-RX-API-DMAC7.html)
MA (1) MA28739B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06014909A (cg-RX-API-DMAC7.html)
NO (1) NO20070343L (cg-RX-API-DMAC7.html)
NZ (1) NZ552510A (cg-RX-API-DMAC7.html)
RU (1) RU2427572C2 (cg-RX-API-DMAC7.html)
SG (1) SG153851A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN06419A1 (cg-RX-API-DMAC7.html)
TW (1) TW200612958A (cg-RX-API-DMAC7.html)
WO (1) WO2006002236A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200700481B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
CA2575188A1 (en) 2004-08-18 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
WO2007011647A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin ksp
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
PT2010528T (pt) 2006-04-19 2017-12-21 Novartis Ag Compostos benzotiazole e benzoxazole 6-o-substituídos e métodos de inibição da sinalização csf-1r
CN101511796B (zh) * 2006-09-05 2012-05-09 协和发酵麒麟株式会社 咪唑衍生物
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
UA97256C2 (ru) 2006-11-13 2012-01-25 Новартис Аг Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
JP2010515687A (ja) * 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体
US8252832B2 (en) * 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
JP2012515749A (ja) 2009-01-26 2012-07-12 ノバルティス アーゲー キネシン阻害化合物の塩及び多形体
US8546434B2 (en) * 2010-04-15 2013-10-01 Novartis Ag Triazole compounds as KSP inhibitors
JP2013525290A (ja) * 2010-04-15 2013-06-20 ノバルティス アーゲー Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物
DE102010025663A1 (de) 2010-06-30 2012-01-05 Karl-Heinz Glüsenkamp Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
PL3086814T3 (pl) * 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
CA2970565A1 (en) 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
SG10201908685QA (en) * 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
WO2016207104A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
JP2018528161A (ja) 2015-06-23 2018-09-27 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤との部位特異的均一複合体
JP2018525334A (ja) 2015-06-23 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
PE20191235A1 (es) * 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
SG11202012608VA (en) 2018-06-18 2021-02-25 Bayer Ag Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
US11236069B2 (en) 2018-12-20 2022-02-01 Amgen Inc. KIF18A inhibitors
CN119241504A (zh) 2021-08-26 2025-01-03 沃拉斯查疗法公司 Kif18a的螺吲哚啉抑制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550959C3 (de) * 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
MXPA01000895A (es) * 1998-08-04 2002-08-20 Astrazeneca Ab Derivados de amida utiles como inhibidores de la produccion de citocinas.
HUP0104060A3 (en) * 1998-09-25 2002-04-29 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors, process for their preparation and medicaments containing them
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU774748B2 (en) 1999-10-27 2004-07-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001227812A1 (en) 2000-05-02 2001-11-12 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
US6683191B2 (en) * 2000-06-05 2004-01-27 Ortho-Mcneil Pharmaceuticals, Inc. Method for synthesis of substituted azole libraries
WO2001094318A2 (en) * 2000-06-05 2001-12-13 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
NZ523774A (en) 2000-08-01 2004-09-24 Sod Conseils Rech Applic Imidazolyl derivatives
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
JP2002190437A (ja) 2000-12-20 2002-07-05 Advantest Corp 電子ビーム露光装置及び校正方法
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
EP1351671A1 (en) 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
US6610723B2 (en) * 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7262187B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
ES2291543T3 (es) 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003050122A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1465888A2 (en) 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7030144B2 (en) * 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
WO2004041809A2 (en) * 2002-05-08 2004-05-21 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
RU2004135554A (ru) * 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
JP2006502974A (ja) * 2002-05-17 2006-01-26 ニューロジェン コーポレイション 置換環縮合イミダゾール誘導体：ｇａｂａａ受容体リガンド
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
BR0311784A (pt) 2002-06-14 2005-03-08 Merck & Co Inc Composto, composição farmacêutica, métodos de tratar ou prevenir o câncer, de modular a formação do fuso mitótico e de inibir a cinesina mitótica e processo para fabricar uma composição farmacêutica
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004001489A1 (ja) 2002-06-19 2003-12-31 Mitsubishi Denki Kabushiki Kaisha 光変調器
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン結合部位
RU2233736C2 (ru) 2002-07-11 2004-08-10 Раховский Вадим Израилович Нанометрическое позиционирующее устройство
AU2003252025A1 (en) 2002-07-17 2004-02-02 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006501201A (ja) 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
KR100492252B1 (ko) 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
WO2004024086A2 (en) 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
CN1681805A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
US7557115B2 (en) * 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
US7476743B2 (en) * 2002-10-11 2009-01-13 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003276514A1 (en) * 2002-11-08 2004-06-07 Neurogen Corporation 4-imidazol-1-ylmethyl-pyrimidine derivatives_as ligands for gabaa receptors
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
US7662581B1 (en) * 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
US7399778B2 (en) 2004-01-16 2008-07-15 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
AU2005214349B2 (en) * 2004-02-12 2011-11-03 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
RU2006138864A (ru) * 2004-04-06 2008-05-20 Чирон Корпорейшн (Us) Ингибиторы митотического кинезина
CA2562846A1 (en) 2004-04-14 2005-10-27 Pfizer Inc. Sulphur-linked imidazole compounds for the treament of hiv
CA2565018A1 (en) 2004-04-28 2005-11-10 Takeda Pharmaceutical Company Limited Fused quinoline derivative and use thereof
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives

Also Published As

Publication number Publication date
NO20070343L (no) 2007-03-05
ZA200700481B (en) 2008-10-29
JP2011256197A (ja) 2011-12-22
US20130017196A1 (en) 2013-01-17
JP2008503501A (ja) 2008-02-07
TNSN06419A1 (en) 2008-02-22
RU2427572C2 (ru) 2011-08-27
SG153851A1 (en) 2009-07-29
EP1765789A1 (en) 2007-03-28
CN1993331A (zh) 2007-07-04
ES2409345T3 (es) 2013-06-26
AU2005258135A1 (en) 2006-01-05
TW200612958A (en) 2006-05-01
IL180147A0 (en) 2007-06-03
US8735599B2 (en) 2014-05-27
BRPI0510929A (pt) 2007-07-17
AU2005258135B2 (en) 2011-09-22
KR20070106961A (ko) 2007-11-06
EP1765789B1 (en) 2013-02-27
US7576221B2 (en) 2009-08-18
CA2571002A1 (en) 2006-01-05
US20060009472A1 (en) 2006-01-12
RU2007101612A (ru) 2008-08-10
WO2006002236A1 (en) 2006-01-05
JP4836280B2 (ja) 2011-12-14
ECSP077183A (es) 2007-02-28
KR101170925B1 (ko) 2012-08-07
MXPA06014909A (es) 2007-02-28
US20090258016A1 (en) 2009-10-15
US8318791B2 (en) 2012-11-27
MA28739B1 (fr) 2007-07-02

Similar Documents

Publication Publication Date Title
NZ552510A (en) N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
AU2008205169B2 (en) Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
AU2007323998B2 (en) Substituted pyrazole and triazole compounds as KSP inhibitors
AU2005301133A1 (en) Indole and benzimidazole derivatives
AU2006279991B2 (en) Substituted imidazole compounds as KSP inhibitors
HK1111995B (en) Substituted imidazole compounds as ksp inhibitors

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: NOVARTIS VACCINES AND DISGNOSTICS, INC., US

Free format text: OLD OWNER(S): CHIRON CORPORATION

RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed